hero image
Irving  Steinberg, PharmD - USC School of Pharmacy. Los Angeles, CA, US

Irving Steinberg, PharmD Irving  Steinberg, PharmD

Associate Dean for Faculty Affairs & Associate Professor of Clinical Pharmacy and Pediatrics | USC School of Pharmacy

Los Angeles, CA, UNITED STATES

Areas of research emphasis include predictive performance of pharmacokinetic models for dosing in children.

Spotlight

Biography

Dr. Irving Steinberg has been with USC since 1985, and is Associate Dean for Faculty Affairs at the USC School of Pharmacy, Associate Professor of Clinical Pharmacy and Pediatrics at the USC School of Pharmacy and Keck School of Medicine, and is Director of the Division of Pediatric Pharmacotherapy in the Department of Pediatrics at the LAC+USC Medical Center. Dr. Steinberg is a graduate of the University of Minnesota, where he completed his residency and an endowed fellowship in infectious diseases and pharmacokinetics. He maintains a very busy clinical consultation practice with bedside teaching of medical residents, represents the Department of Pediatrics on the Pharmacy and Therapeutics Committee, and on the Antimicrobial and Medication Safety Subcommittees at County-USC, and has served on medical expert panels for the Department of Health Services. He has published and presented numerous scientific papers and book chapters on pharmacokinetics, antimicrobials and drug resistance, antiepileptic and cardiovascular drugs. He is a content editor on anivirals and antifungals for the forthcoming issue of the American Academy of Pediatrics' Redbook. Areas of research emphasis include predicitve performance of pharmacokinetic models for dosing in children and novel pharmacotherapeutic applications of drugs such as amphotericin and erythromycin in neonates. This diversity in areas of expertise is reflected in his programmatic efforts and teaching, from bedside to classroom, at USC. He has trained numerous pediatric pharmacotherapy residents & fellows who have gone on to distinguished careers. Additionally, Dr. Steinberg is a noted national speaker for many physician and pharmacist audiences, and has given hundreds of lectures and continuing education programs in 43 states in the US. His expertise in legal medicine is nationally regarded, and is sought-after in court and arbitration disputes involving pharmacologic and toxicologic issues.

Areas of Expertise (9)

COVID-19

Pediatric Pharmacotherapeutics

Maternal-Fetal Pharmacology

Infectious Diseases

Critical Care Pharmacology and Toxicology

Pharmacokinetics & Pharmacodynamics

Antibiotic Resistance

Legal/Forensic Medicine & Pharmacology

Coronavirus

Accomplishments (1)

Top 1% of Expert Witnesses

Dr. Steinberg serves as a medical expert witness in many difficult forensic cases, and his expertise was recognized in 2012 as among the Top 1% of Expert Witnesses for Medical Malpractice Litigation in California (one of only seven pharmacologists).

Selected Articles (3)

Acyclovir dosing and acute kidney injury: Deviations and direction The Journal of Pediatrics

Irving Steinberg

2015

When admitted to the hospital almost all patients will receive a standard battery of blood tests, which includes a Complete Blood Count (CBC). Often a primary care office will order such work for their patients simply to have a baseline, and many specialists will do so as a means to monitor drug reactions and overall health.

view more

Case 3: fever, vomiting, and increased sleepiness in a 4-year-old girl Pediatrics in Review

Irving Steinberg

2015

view more

Renal tolerance with the use of intralipid-amphotericin B in low-birth-weight neonates American Journal of Perinatology

Irving Steinberg

1997

Amphotericin B is still the first-line therapy for neonatal fungal infections. With several comparative trials of intralipid-based amphotericin B (IL-AmB) demonstrating its clinical effectiveness and reduced renal toxicity in adults, we examined the renal tolerance and infection outcome in low-birth-weight infants in our 48-bed NICU treated with IL-AmB. Over 2 years, 52 patients (58 courses) received > or = 10 days of IL-AmB. Nineteen charts (23 episodes) were randomly accessed and reviewed. Mean birthweight = 747 grams, gestational age = 25.6 weeks, total IL-AmB dosage = 19.8 +/- 3.3 mg/kg (n = 23); 20 of these episodes were fungal culture positive (9 fungemias). Only one patient (who died during therapy) had a rise in creatinine of > 0.3 mg/dL. Overall, serum creatinine decreased significantly after Day 10 of IL-AmB therapy, from 0.93 +/- 0.42 mg/dL at baseline, to 0.54 +/- 0.24 after 19 days of therapy (p < 0.0001). Serial urine output, serum potassium and potassium supplementation data showed no significant differences from baseline. No interruption of therapy nor infusion reactions occurred. Only one death occurred attributable to fungal infection. Intralipid-amphotericin B may provide an effective alternative in the antifungal therapy of low birthweight neonates, without nephrotoxicity. Further prospective, comparative trials are warranted.

view more